Edward Yu
Overview
Explore the profile of Edward Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
1976
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramasamy K, Vij R, Kuter D, Cella D, Durie B, Abonour R, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Jan;
PMID: 39799046
Background: This analysis explored real-world characteristics, treatment patterns and clinical outcomes in patients with relapsed or refractory multiple myeloma (RRMM) previously treated with lenalidomide and an anti-CD38 monoclonal antibody (mAb)...
2.
Terebelo H, Omel J, Wagner L, Hardin J, Rifkin R, Ailawadhi S, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Nov;
25(1):58-66.
PMID: 39603959
Background: Over the last 15 years, improvements in patient management and treatments have been associated with longer survival in patients with multiple myeloma (MM). The Connect MM Registry is a...
3.
Ailawadhi S, Lee H, Omel J, Toomey K, Hardin J, Gasparetto C, et al.
Blood Cancer J
. 2024 Nov;
14(1):198.
PMID: 39528478
Limited data exist on the effects of induction treatment in patients with newly diagnosed multiple myeloma (NDMM) and renal impairment (RI), who may also be ineligible for autologous stem cell...
4.
Yu E, Tai P, Perera F, Jordan K
Cureus
. 2024 Sep;
16(8):e67962.
PMID: 39328646
Photodynamic therapy (PDT) has been used to treat cancers. It has also been used to treat infectious diseases and inflammatory conditions. PDT promotes wound healing, while clinical use of PDT...
5.
Abonour R, Lee H, Rifkin R, Ailawadhi S, Omel J, Hardin J, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Jul;
24(10):e336-e343.
PMID: 39033038
Background: Lenalidomide (R), bortezomib (V), and dexamethasone (d) is a standard-of-care regimen in newly diagnosed multiple myeloma (NDMM); however, characteristics and outcomes for nontransplanted patients receiving frontline RVd are not...
6.
Stults C, Mazor K, Cheung M, Ruo B, Li M, Walker A, et al.
J Particip Med
. 2024 Mar;
16:e50242.
PMID: 38483458
Background: Effective primary care necessitates follow-up actions by the patient beyond the visit. Prior research suggests room for improvement in patient adherence. Objective: This study sought to understand patients' views...
7.
Ballas L, Ailawadhi S, Narang M, Gasparetto C, Lee H, Hardin J, et al.
Pract Radiat Oncol
. 2023 Nov;
14(2):e141-e149.
PMID: 37984714
Purpose: Radiation therapy (RT) is an important treatment modality for patients with multiple myeloma (MM). Although patients are living longer with MM, they are more likely to have comorbidities related...
8.
Gulstene S, Lang P, Qu X, Laba J, Yaremko B, Rodrigues G, et al.
Radiother Oncol
. 2023 Nov;
190:109976.
PMID: 37918636
Purpose: Response EvaluationCriteriain Solid Tumors (RECIST) is commonly used to assess response to anti-cancer therapies. However, its application after lung stereotactic ablative radiotherapy (SABR) is complicated by radiation-induced lung changes....
9.
Patel J, Erba H, Savona M, Grinblatt D, Clark M, Clive T, et al.
J Mol Diagn
. 2023 Jul;
25(8):611-618.
PMID: 37517825
Genomic data variability from laboratory reports can impact clinical decisions and population-level analyses; however, the extent of this variability and the impact on the data's value are not well characterized....
10.
Chau O, Islam A, Lock M, Yu E, Dinniwell R, Yaremko B, et al.
J Nucl Med Technol
. 2023 May;
51(2):133-139.
PMID: 37192822
Our purpose was to investigate the utility of F-FDG PET/MRI and serial blood work to detect early inflammatory responses and cardiac functionality changes at 1 mo after radiation therapy (RT)...